Resistant KRAS(G12C) Inhibitor Subclones Exhibit Heterogeneous Alterations

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• KRAS(G12C) mutations are key drivers in various cancers.
• KRAS(G12C) inhibitors (G12Ci) offer targeted therapy options.
• Acquired resistance limits the long-term efficacy of G12Ci.

Purpose of the Study:

• To investigate the molecular mechanisms underlying acquired resistance to KRAS(G12C) inhibitors.
• To characterize the heterogeneity of resistance alterations in preclinical models or patient samples.

Main Methods:

• Utilized genomic profiling techniques (e.g., whole-exome sequencing, targeted sequencing) to identify genetic alterations.
• Employed cell line models and/or patient-derived xenografts to study resistance development.
• Analyzed longitudinal samples to track the evolution of resistance.

Main Results:

• Observed a diverse array of genetic alterations upon G12Ci treatment, rather than a single predominant mechanism.
• Identified alterations in various signaling pathways, including downstream effectors and bypass pathways.
• Demonstrated that resistance can arise through multiple, non-exclusive genetic events.

Conclusions:

• KRAS(G12C) inhibitor resistance is characterized by significant heterogeneity.
• The lack of a dominant resistance mechanism complicates the development of universal resensitization strategies.
• Further research is needed to understand and overcome the multifaceted nature of G12Ci resistance.